• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Endokrynol Pol . Higher rate of COVID-19 mortality in patients with type 1 than type 2 diabetes: a nationwide study

tetano

Editor, Senior Moderator
Endokrynol Pol


. 2022 Feb 4.
doi: 10.5603/EP.a2022.0008. Online ahead of print.
Higher rate of COVID-19 mortality in patients with type 1 than type 2 diabetes: a nationwide study


Ibrahim Demirci[SUP] 1 [/SUP], Cem Haymana[SUP] 2 [/SUP], Ilker Tasci[SUP] 3 [/SUP], Ilhan Satman[SUP] 4 5 [/SUP], Aysegul Atmaca[SUP] 6 [/SUP], Mustafa Sahin[SUP] 7 [/SUP], Naim Ata[SUP] 8 [/SUP], Ugur Unluturk[SUP] 9 [/SUP], Erman Cakal[SUP] 10 [/SUP], Selcuk Dagdelen[SUP] 9 [/SUP], Ibrahim Sahin[SUP] 11 [/SUP], Osman Celik[SUP] 12 [/SUP], Derun Ertugrul[SUP] 13 [/SUP], Tevfik Demir[SUP] 14 [/SUP], Rifat Emral[SUP] 7 [/SUP], Murat Caglayan[SUP] 15 [/SUP], Serpil Salman[SUP] 16 [/SUP], Suayip Birinci[SUP] 17 [/SUP], Alper Sonmez[SUP] 18 [/SUP]



Affiliations

Abstract

Introduction: COVID-19 disease has a worse prognosis in patients with diabetes, but comparative data about the course of COVID-19 in patients with type 1 (T1DM) and type 2 diabetes (T2DM) are lacking. The purpose of this study was to find out the relative clinical severity and mortality of COVID-19 patients with T1DM and T2DM.
Material and methods: A nationwide retrospective cohort of patients with confirmed (PCR positive) COVID-19 infection (n = 149,671) was investigated. After exclusion of individuals with unspecified diabetes status, the adverse outcomes between patients with T1DM (n = 163), T2DM (n = 33,478) and those without diabetes (n = 115,108) were compared by using the propensity score matching method. The outcomes were hospitalization, the composite of intensive care unit (ICU) admission and/or mechanical ventilation, and mortality.
Results: The patients with T1DM had higher mortality than the age- and gender-matched patients with T2DM (n = 489) and those without diabetes (n = 489) (p < 0.001). After further adjustment for the HbA1c, and microvascular and macrovascular complications, the odds of mortality (OR: 3.35, 95% CI: 1.41-7.96, p = 0.006) and ICU admission and/or mechanical ventilation (OR: 2.95, 95% CI: 1.28-6.77, p = 0.011) were significantly higher in patients with T1DM compared to those with T2DM. Older age (OR: 1.06, 95% CI: 1.01-1.12, p = 0.028) and lymphopaenia (OR: 5.13, 95% CI: 1.04-25.5, p = 0.045) were independently associated with mortality in patients with T1DM.
Conclusions: Patients with T1DM had worse prognosis of COVID-19 compared to T2DM patients or those without diabetes. These cases should be cared for diligently until more data become available about the causes of increased COVID-19 mortality in T1DM.

Keywords: COVID-19; T1DM; Turkey; coronavirus; diabetes mellitus; mortality; type 1 diabetes.
 
Back
Top Bottom